Clinical trials involving ICB for BC focus on a subpopulation of BC with a triple negative (TN) subtype or a human epidermal growth factor receptor-2 (HER2) positive subtype [6, 7], and the local tumor microenvironment (TME) is considered a pivotal determinant of therapeutic efficiency and prognosis [8]. This evidence concerns the gene ERBB2 and breast cancer.